EssilorLuxottica Société Anonyme (ENXTPA:EL) Expands Meta Glasses Push, Is It A Bargain?

EssilorLuxottica Société anonyme (ENXTPA:EL) is back in focus after expanding its collaboration with Meta on AI-powered Meta Glasses, while also partnering with Applied Materials on next-generation intelligent optical systems for smart eyewear.

See our latest analysis for EssilorLuxottica Société anonyme.

Despite the fanfare around Meta Glasses and the Applied Materials partnership, EssilorLuxottica Société anonyme’s 7 day share price return is down 8.39% and the year to date share price return is down 36.67%. However, the 5 year total shareholder return of 18.65% points to a more resilient longer term record.

If smart eyewear and AI hardware interest you, this is a good moment to scan the wider opportunity set through our screener of 49 AI infrastructure stocks

So with EssilorLuxottica Société anonyme’s shares weaker this year despite new AI glasses partnerships and indications of a discount to some valuation estimates, should you see mispricing here or assume the market is already accounting for future growth?

Most Popular Narrative: 40.5% Undervalued

Against EssilorLuxottica Société anonyme’s last close at €168.15, the most followed narrative places fair value at about €282, which frames the current share price as a steep discount and puts the focus firmly on what is being assumed about future growth, margins and cash flows.

Investments in smart eyewear, AI-enabled vision solutions, and MedTech (Ray-Ban Meta, Oakley Meta, Nuance Audio, acquisition of Optegra Eye Clinics) capitalize on long-term demand for technologically advanced and personalized eye health platforms, catalyzing product mix upgrades and higher ASPs, which will benefit gross margin and future earnings.

Read the complete narrative.

Want to understand why this narrative sees so much upside for EssilorLuxottica Société anonyme? The fair value hinges on faster top line growth, richer margins and a premium earnings multiple. Curious which revenue runway, profitability step up and valuation level have been baked into that story? The full narrative lays out the exact assumptions that bridge today’s price to that higher fair value.

Result: Fair Value of €282.39 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, EssilorLuxottica Société anonyme’s push into smart eyewear and premium MedTech could face adoption, margin and regulatory setbacks that challenge the positive growth narrative.

Find out about the key risks to this EssilorLuxottica Société anonyme narrative.

Another View: EssilorLuxottica Société anonyme Looks Expensive On Earnings

The first narrative leans heavily on discounted cash flows and long term growth for EssilorLuxottica Société anonyme, but the current P/E of 33.4x tells a different story. It sits above the European Medical Equipment average of 24.9x and above a fair ratio of 27.1x. This suggests there is less margin for error if growth or margins disappoint.

Put simply, the market is already paying more per euro of earnings than both peers and the fair ratio imply. Any slip in execution could therefore have a sharper impact on the share price than a pure DCF view might suggest. Which lens do you want to rely on when expectations are this stretched?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Seeing both bullish and cautious sentiment around EssilorLuxottica Société anonyme? Take a moment to review the full picture yourself and weigh the trade off between its concerns and potential upsides by checking the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond EssilorLuxottica Société anonyme?

If EssilorLuxottica Société anonyme has caught your attention, use this moment to widen your watchlist and pressure test your convictions against other stocks with strong fundamentals.

• Spot potential bargains early by scanning screener containing 496 high quality undiscovered gems that pair solid business quality with less crowded investor attention.
• Strengthen your portfolio’s core with the solid balance sheet and fundamentals stocks screener (415 results) and focus on companies backed by healthier finances.
• Reduce portfolio stress by checking 286 resilient stocks with low risk scores that screen for more resilient business profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.